---
title: "Zimmer Biomet Holdings, Inc. (ZBH.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ZBH.US.md"
symbol: "ZBH.US"
name: "Zimmer Biomet Holdings, Inc."
industry: "Health Care Equipment"
datetime: "2026-03-14T05:16:12.020Z"
locales:
  - [en](https://longbridge.com/en/quote/ZBH.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ZBH.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ZBH.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ZBH.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ZBH.US.md)


# Zimmer Biomet Holdings, Inc. (ZBH.US)

## Company Overview

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.

| Item | Detail |
|------|--------|
| Industry | Health Care Equipment |
| Exchange | US Market |
| Website | [www.zimmerbiomet.com](https://www.zimmerbiomet.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-14T04:30:16.000Z

**Overall: C (0.45)**

**Industry**: Health Care Equipment

| Metric | Value |
|--------|-------|
| Industry Ranking | 43 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Large - The company has stable operations, allowing for dependable long-term returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.20% |  |
| Net Profit YoY | -21.98% |  |
| P/B Ratio | 1.44 |  |
| Dividend Ratio | 1.03% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 18234766772.80 |  |
| Revenue | 8231500000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 5.60% | C |
| Profit Margin | 8.57% | B |
| Gross Margin | 69.71% | A |
| Revenue YoY | 7.20% | C |
| Net Profit YoY | -21.98% | D |
| Total Assets YoY | 8.08% | B |
| Net Assets YoY | 1.84% | C |
| Cash Flow Margin | 1167.42% | B |
| OCF YoY | 7.20% | C |
| Turnover | 0.37 | C |
| Gearing Ratio | 44.98% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zimmer Biomet Holdings, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "7.20%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-21.98%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.44",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "1.03%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "18234766772.80",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "8231500000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "5.60%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "8.57%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "69.71%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "7.20%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-21.98%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.08%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "1.84%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "1167.42%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "7.20%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.37",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "44.98%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 25.86 | 21/188 | 24.78 | 22.54 | 20.60 |
| PB | 1.44 | 45/188 | 1.62 | 1.51 | 1.43 |
| PS (TTM) | 2.22 | 58/188 | 2.61 | 2.40 | 2.25 |
| Dividend Yield | 1.03% | 15/188 | 1.05% | 1.01% | 0.94% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Delcath (DCTH.US) | C | A | B | A | A | A |
| 02 | Abbott Laboratories (ABT.US) | B | C | C | C | C | B |
| 03 | Intuitive Surgical (ISRG.US) | A | B | C | A | B | B |
| 04 | Stryker (SYK.US) | A | B | B | C | B | B |
| 05 | Boston Scientific (BSX.US) | B | B | C | C | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-03-11T04:00:00.000Z

Total Analysts: **29**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 21% |
| Overweight | 3 | 10% |
| Hold | 17 | 59% |
| Underweight | 1 | 3% |
| Sell | 2 | 7% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 93.20 |
| Highest Target | 130.00 |
| Lowest Target | 88.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ZBH.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ZBH.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ZBH.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ZBH.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**